Benmelstobart

Phase 3Small molecule

SSun Yat-sen University

Benmelstobart is one of 221 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

220

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaNot yet recruiting

Lung CancerNot yet recruiting

Lung AdenocarcinomaRecruiting

Breast CancerRecruiting

Neoadjuvant TherapyNot yet recruiting

Adjuvant TherapyNot yet recruiting

BenmelstobartRecruiting

Efficacy and SafetyNot yet recruiting

Nasopharyngeal CarcinomaPhase 3

Not yet recruiting

Lung CancerPhase 3

Not yet recruiting

Lung AdenocarcinomaPhase 2

Recruiting

Breast CancerPhase 2

Recruiting

Neoadjuvant TherapyPhase 2

Not yet recruiting

Adjuvant TherapyPhase 3

Not yet recruiting

BenmelstobartPhase 2

Recruiting

Efficacy and SafetyPreclinical

Not yet recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Benmelstobart

SSun Yat-sen University

Phase 3

2 2

Lexiscan

Astellas

Preclinical

1 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 5

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 6

Tianeptine

Pfizer

Preclinical

1 7

Ablavar

LLantheus Medical Imaging

Preclinical

2 8

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Naltrexone/bupropion

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Efficacy and Safety

NCT06603974

Q4 2027

Phase 2Not yet recruiting

Neoadjuvant Therapy

NCT06699498

Post-ApprovalNot yet recruiting

Lung Cancer

NCT06931145

Q3 2028

Phase 2Recruiting

Breast Cancer

NCT05582499

Q4 2028

Phase 2Recruiting

Benmelstobart

NCT06733051

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting·FFudan University·Phase 2·NCT05582499·716 enrolled

A Phase II, Open-Label, Randomized Study Comparing Antiangiogenic Therapy Combined With Immunotherapy and Capecitabine Versus Investigator's Choice in Patients With Circulating Tumor DNA-Positive Stage II-III Triple-Negative Breast Cancer Who With Residual Disease After Neoadjuvant Therapy

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06992336·430 enrolled

Benmelstobart1 trial

Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)

Recruiting·SSun Yat-sen University·Phase 2·NCT06733051·47 enrolled

Lung Adenocarcinoma1 trial

Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06528847·62 enrolled

Efficacy and Safety1 trial

The Efficacy and Safety of Benmelstobart for GC/EGC

Not yet recruiting·XXijing Hospital·N/A·NCT06603974·48 enrolled

Nasopharyngeal Carcinoma1 trial

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Not yet recruiting·SSun Yat-sen University·Phase 3·NCT07385079·412 enrolled

6 more indications

Adjuvant Therapy1 trial

Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations

Not yet recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 3·NCT06955325·270 enrolled

Lung Cancer1 trial

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Not yet recruiting·PPeking Union Medical College Hospital·Phase 4·NCT06931145·50 enrolled

Neoadjuvant Therapy1 trial

Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06699498·45 enrolled

Nasopharyngeal Cancinoma (NPC)1 trial

A Risk-Adapted, Multicenter, Prospective Clinical Trial of Anlotinib Combined With a PD-L1 Inhibitor in Locoregionally Advanced Nasopharyngeal Carcinoma

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07904819·214 enrolled

Non-Clear Cell Renal Cell Carcinoma1 trial

A Randomized, Controlled, Prospective, Multicenter, Phase III Study of Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT07881900·126 enrolled

Malignant Neoplasms of Digestive Organs1 trial

An Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of the LM-302 Combination With Other Anti-tumor Treatment in Subjects With CLDN18.2-positive Advanced Gastro-Intestinal Cancer.

Recruiting·LLaNova Medicines Zhejiang Co., Ltd.·Phase 2·NCT05934331·632 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Benmelstobart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Benmelstobart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Benmelstobart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSun Yat-sen University

Benmelstobart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q3 2028

Q4 2028

Trials by Indication[1]

Breast Cancer2 trials

Benmelstobart1 trial

Lung Adenocarcinoma1 trial

Efficacy and Safety1 trial

Nasopharyngeal Carcinoma1 trial

Adjuvant Therapy1 trial

Lung Cancer1 trial

Neoadjuvant Therapy1 trial

Nasopharyngeal Cancinoma (NPC)1 trial

Non-Clear Cell Renal Cell Carcinoma1 trial

Malignant Neoplasms of Digestive Organs1 trial

References

Drug Info

Quick Facts

Related News